SSTR5 and pituitary gland adenoma: Although BIM-23A760 has been withdrawn from clinical development after discovering a dopaminergic metabolite that accumulates and interferes with the activity of the parent compound in vivo19, 27, it is still considered a good prototype molecule and therefore, the results generated using primary pituitary cell cultures from pituitary adenomas and normal pituitaries may be really useful in predicting the response to members of this class of compounds (i.e. new generation of chimeric agonist for sst2/sst5/D2 receptors) that may be used for clinical purposes in the future.